The global next-gen robotic surgical systems market is driven by the increasing prevalence of chronic diseases and rising demand for minimally invasive surgeries. According to the World Health Organization (WHO), over 1.71 billion people worldwide are affected by musculoskeletal conditions, many of which require surgical intervention. Additionally, the American Cancer Society reports that approximately 1.96 million new cancer cases were diagnosed in the U.S. in 2023, fueling demand for precision-driven surgical technologies, particularly in oncology. Robotic systems are increasingly utilized in procedures such as prostatectomies and hysterectomies, with studies showing that robotic-assisted surgeries reduce hospital stays by 20–25% compared to traditional open surgeries, enhancing recovery times and patient outcomes. With advancements in AI integration and haptic feedback, these systems are poised to address the growing surgical demand in aging populations and regions with high disease prevalence.
